A meta-analysis of pharmacotherapy for social anxiety disorder: an examination of efficacy, moderators, and mediators

References

• Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychait. 2005;62(6):593–602.
   PubMed Web of Science ®Google Scholar
• Furmark T. Social phobia: overview of community surveys. Acta Psychiat Scand. 2002;105(2):84–93.
   PubMed Web of Science ®Google Scholar
• Katzelnick DJ, Kobak KA, DeLeire T, et al. Impact of generalized social anxiety disorder in managed care. Am J Psychiat. 2001;158(12):1999–2007.
   PubMed Web of Science ®Google Scholar
• Kushnir J, Marom S, Mazar M, et al. The link between social anxiety disorder, treatment outcome, and sleep difficulties among patients receiving cognitive behavioral group therapy. Sleep Med. 2014;15(5):515–521.
   PubMed Web of Science ®Google Scholar
• Hofmann SG, Smits JAJ. Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials. J Clin Psychiat. 2008;69(4):621–632.
   PubMed Web of Science ®Google Scholar
• Mayo-Wilson E, Dias S, Mavranezouli I, et al. Psychological and pharmacological interventions for social anxiety disorder in adults: a systematic review and network meta-analysis. Lancet Psychiat. 2014;1(5):368–376.
   PubMed Web of Science ®Google Scholar
• Davis ML, Smits JAJ, Hofmann SG. Update on the efficacy of pharmacotherapy for social anxiety disorder: a meta-analysis. Exp Op Pharm. 2014;15(16):2281–2291.
   PubMed Web of Science ®Google Scholar
• Hofmann SG. Cognitive mediation of treatment change in social phobia. J Consult Clin Psychol. 2004;72(3):392–399.
   Web of Science ®Google Scholar
• Hofmann SG. Cognitive processes during fear acquisition and extinction in animals and humans: implications for exposure therapy of anxiety disorders. Clin Psychol Rev. 2008;28(2):199–210.
   PubMed Web of Science ®Google Scholar
• Llorca PM. Review: the antidepressant agomelatine improves the quality of life of depressed patients: implications for remission. J Psychopharmacol. 2010;24:21–26.
   PubMed Web of Science ®Google Scholar
• Stein MB, Liebowitz MR, Lydiard RB, et al. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. Jama. 1998;280(8):708–713.
   PubMed Web of Science ®Google Scholar
• Olatunji BO, Cisler JM, Tolin DF. Quality of life in the anxiety disorders: a meta-analytic review. Clin Psychol Rev. 2007;27(5):572–581.
   PubMed Web of Science ®Google Scholar
• Rosenthal R. Meta-analytic procedures for social research. Thousand Oaks: Sage; 1991.
   Google Scholar
• Borenstein M, Rothstein H. Comprehensive meta-analysis: A computer program for research synthesis. Englewood: Biostat Inc; 1999.
   Google Scholar
• Cheung MWL. metaSEM: an R package for meta-analysis using structural equation modeling. Front Psychol. 2015;5:1–7.
   Web of Science ®Google Scholar
• Gu J, Strauss C, Bond R, et al. How do mindfulness-based cognitive therapy and mindfulness-based stress reduction improve mental health and wellbeing? A systematic review and meta-analysis of mediation studies. Clin Psychol Rev. 2015;37:1–12.
   PubMed Web of Science ®Google Scholar
• Lipsey MW, Wilson DB. Practical meta-analysis. Thousand Oaks CA: Sage Publications; 2001.
   Google Scholar
• Allgulander C. Paroxetine in social anxiety disorder: a randomized placebo-controlled study. Acta Psychiatr Scand. 1999;100(3):193–198.
   PubMed Web of Science ®Google Scholar
• Allgulander C, Mangano R, Zhang J, et al. Efficacy of venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum Psychopharm Clin. 2004;19(6):387–396.
   PubMed Web of Science ®Google Scholar
• Asakura S, Tajima O, Koyama T. Fluvoxamine treatment of generalized social anxiety disorder in Japan: a randomized double-blind, placebo-controlled study. The Int J Neuropsychop. 2007;10(2):263–274.
   PubMed Web of Science ®Google Scholar
• Baldwin D, Bobes J, Stein D, et al. Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group. Br J Psychiatry. 1999;175(2):120–126.
   PubMed Web of Science ®Google Scholar
• Barnett SD, Kramer ML, Casat CD, et al. Efficacy of olanzapine in social anxiety disorder: a pilot study. J Psychopharmacol. 2002;16(4):365–368.
   PubMed Web of Science ®Google Scholar
• Blanco C, Heimberg R, Schneier F, et al. A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder. Arch Gen Psychiatry. 2010;67(3):286–295.
   PubMed Web of Science ®Google Scholar
• Blomhoff S, Haug T, Hellström K, et al. Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. Br J Psychiatry. 2001;179(1):23–30.
   PubMed Web of Science ®Google Scholar
• Clark D, Ehlers A, Mcmanus F, et al. Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial. J Consult Clin Psychol. 2003;71(6):1058–1067.
   PubMed Web of Science ®Google Scholar
• Davidson JR, Potts N, Richichi E, et al. Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol. 1993;13(6):423–428.
   PubMed Web of Science ®Google Scholar
• Davidson J, Foa E, Huppert J, et al. Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Arch Gen Psychiat. 2004a;61(10):1005–1013. .
   PubMed Web of Science ®Google Scholar
• Davidson J, Yaryura-Tobias J, DuPont R, et al. Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol. 2004b;24:118–125.
   PubMed Web of Science ®Google Scholar
• Fahlén T, Nilsson HL, Borg K, et al. Social phobia: the clinical efficacy and tolerability of the monoamine oxidase-A and serotonin uptake inhibitor brofaromine. A double-blind placebo-controlled study. Acta Psychiat Scand. 1995;92(5):351–358.
   PubMed Web of Science ®Google Scholar
• Feltner DE, Liu-Dumaw M, Schweizer E, et al. Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fixed-dose study. Int Clin Psychopharmacol. 2011;26:213–220.
   PubMed Web of Science ®Google Scholar
• Furmark T, Appel L, Michelgåard A, et al. Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biol Psychiat. 2005;58(2):132–142.
   PubMed Web of Science ®Google Scholar
• Gelernter CS, Uhde TW, Cimbolic P, et al. Cognitive–behavioral and pharmacological treatments of social phobia: a controlled study. Arch Gen Psychiatry. 1991;48:938–945.
   PubMed Web of Science ®Google Scholar
• Gergel I, Pitts C, Oakes R, et al. 14-27-Significant improvement in symptoms of social phobia after paroxetine treatment. Biol Psychiat. 1997;42(1):26S.
   Google Scholar
• Giménez M, Ortiz H, Soriano-Mas C, et al. Functional effects of chronic paroxetine versus placebo on the fear, stress and anxiety brain circuit in social anxiety disorder: initial validation of an imaging protocol for drug discovery. Euro Neuropsychopharmacol. 2014;24(1):105–116.
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. A randomized, double-blind, parallel-group, placebo-controlled, forced-dose titration study evaluating the efficacy and safety of a new chemical entity (NCE) and paroxetine in subjects with social anxiety disorder. GSKClinical Study Register [wwwgskclinicalstudyregistercom]. 2006.
   Google Scholar
• Heimberg RG, Liebowitz MR, Hope DA, et al. Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12 week outcome. Arch Gen Psychiat. 1998;55:1133–1141.
   PubMed Web of Science ®Google Scholar
• Kasper S, Stein D, Loft H, et al. Escitalopram in the treatment of social anxiety disorder randomised, placebo-controlled, flexible-dosage study. Br J Psychiatry. 2005;186(3):222–226.
   PubMed Web of Science ®Google Scholar
• Katschnig H. Moclobemide in social phobia. Euro Arch Psychiat Clin Neurosci. 1997;247(2):71–80.
   PubMed Web of Science ®Google Scholar
• Katzelnick D, Kobak K, Greist J, et al. Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatry. 1995;152(9):1368–1371.
   PubMed Web of Science ®Google Scholar
• Kobak K, Greist J, Jefferson J, et al. Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study. J Clin Psychopharmacol. 2002;22(3):257–262.
   PubMed Web of Science ®Google Scholar
• Kobak KA, Taylor LV, Warner G, et al. St John’s wort versus placebo in social phobia: results from a placebo-controlled pilot study. J Clin Psychopharmacol. 2005;25(1):51–58.
   PubMed Web of Science ®Google Scholar
• Lader M, Stender K, Bürger V, et al. Efficacy and tolerability of escitalopram in 12-and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. Depress Anxiety. 2004;19(4):241–248.
   PubMed Web of Science ®Google Scholar
• Lepola U, Bergtholdt B, St Lambert J, et al. Controlled-release paroxetine in the treatment of patietns with social anxiety disorder. J Clin Psychiat. 2004;65(2):222–229.
   PubMed Web of Science ®Google Scholar
• Liebowitz M, Schneier F, Campeas R, et al. Phenelzine vs atenolol in social phobia: a placebo-controlled comparison. Arch Gen Psychiatry. 1992;49(4):290–300.
   PubMed Web of Science ®Google Scholar
• Liebowitz M, Stein M, Tancer M, et al. A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in treatment of generalized social anxiety disorder. J Clin Psychiatry. 2002;63(1):66–74.
   PubMed Web of Science ®Google Scholar
• Liebowitz M, Demartinis N, Weihs K, et al. Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study. J Clin Psychiatry. 2003;64(7):785–792.
   PubMed Web of Science ®Google Scholar
• Liebowitz M, Gelenberg A, Munjack D. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry. 2005a;62(2):190–198.
   PubMed Web of Science ®Google Scholar
• Liebowitz MR, Mangano RM, Bradwejn J, et al. A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. J Clin Psychiat. 2005b;66:238–247.
   PubMed Web of Science ®Google Scholar
• Lott M, Greist JH, Jefferson JW, et al. Brofaromine for social phobia: a multicenter, placebo-controlled, double-blind study. J Clin Psychopharmacol. 1997;17(4):255–260.
   PubMed Web of Science ®Google Scholar
• Noyes R, Moroz G, Davidson J, et al. Moclobemide in social phobia: a controlled dose-response trial. J Clin Psychopharmacol. 1997;17(4):247–254.
   PubMed Web of Science ®Google Scholar
• Oosterbaan DB, Van Balkom AJ, Spinhoven P, et al. Cognitive therapy versus moclobemide in social phobia: a controlled study. Clin Psychol Psychothe. 2001;8(4):263–273.
   Web of Science ®Google Scholar
• Pande AC, Davidson JR, Jefferson JW, et al. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol. 1999;19(4):341–348.
   PubMed Web of Science ®Google Scholar
• Pande AC, Feltner DE, Jefferson JW, et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J Clin Psychopharmacol. 2004;24(2):141–149.
   PubMed Web of Science ®Google Scholar
• Pfizer. A 10-week, randomized, double-blind, placebo-controlled study of paroxetine and pregabalin in patients with social phobia (1008-081 and 1008-153). Web Synopsis Protocol 1008-081/153 – 21 June 2007 – Final; 2007.
   Google Scholar
• Rickels K, Mangano R, Khan A. A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. J Clin Psychopharmacol. 2004;24(5):488–496.
   PubMed Web of Science ®Google Scholar
• Schneier F, Goetz D, Campeas R, et al. Placebo-controlled trial of moclobemide in social phobia. Br J Psychiatry. 1998;172(1):70–77.
   PubMed Web of Science ®Google Scholar
• Schutters SI, Van Megen HJ, Van Veen JF, et al. Mirtazapine in generalized social anxiety disorder: a randomized, double-blind, placebo-controlled study. Int Clin Psychopharmacol. 2010;25(5):302–304.
   PubMed Web of Science ®Google Scholar
• Stein MB, Fyer AJ, Davidson JR, et al. Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am J Psychiat. 1999;156(5):756–760.
   PubMed Web of Science ®Google Scholar
• Stein D, Cameron A, Amrein R, et al. Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder. Int Clin Psychopharmacol. 2002;17(4):161–170.
   PubMed Web of Science ®Google Scholar
• Stein MB, Pollack MH, Bystritsky A, et al. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology. 2005;177(3):280–288.
   PubMed Web of Science ®Google Scholar
• Tauscher J, Kielbasa W, Iyengar S, et al. Development of the 2nd generation neurokinin-1 receptor antagonist LY686017 for social anxiety disorder. Eur Neuropsychopharmacol. 2010;20:80–87.
   PubMed Web of Science ®Google Scholar
• The International Multicenter Clinical Trial Group on moclobemide in social phobia. Moclobemide in social phobia. A double-blind, placebo-controlled clinical study. Eur Arch Psychiatry Clin Neurosci. 1997; 247(2):71–80.
   PubMed Web of Science ®Google Scholar
• Van Ameringen M, Lane R, Walker J, et al. Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. Am J Psychiatry. 2001;158(2):275–281.
   PubMed Web of Science ®Google Scholar
• Van Vliet IM, Den Boer JA, Westenberg HG. Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor. Euro Neuropsychopharmacol. 1992;2(1):21–29.
   PubMedGoogle Scholar
• Van Vliet IM, Den Boer JA, Westenberg HG. Psychopharmacological treatment of social phobia: a double blind placebo controlled study with fluvoxamine. Psychopharmacol. 1994;115(1–2):128–134.
   PubMed Web of Science ®Google Scholar
• Versiani M, Nardi AE, Mundim FD, et al. Pharmacotherapy of social phobia: a controlled study with moclobemide and phenelzine. Brit J Psychiat. 1992;161(3):353–360.
   PubMed Web of Science ®Google Scholar
• Westenberg H, Stein D, Yang H, et al. A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol. 2004;24(1):49–55.
   PubMed Web of Science ®Google Scholar
• Zhang W, Connor KM, Davidson JR. Levetiracetam in social phobia: a placebo controlled pilot study. J Psychopharmacol. 2005;19(5):551–553.
   PubMed Web of Science ®Google Scholar
• Rosenthal R. The “file drawer problem” and tolerance for null results. Psychol Bull 1979;85:638–641.
   Google Scholar
• Orwin RG. A fail-safe N for effect size in meta-analysis. J Educ Stat. 1983;8(2):157–159.
   Google Scholar
• Duval S, Tweedie R. Trim and fill: a simple funnel plot–based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56(2):455–463.
   PubMed Web of Science ®Google Scholar
• Stahl SM. Mechanism of action of serotonin selective reuptake inhibitors: serotonin receptors and pathways mediate therapeutic effects and side effects. J Affect Disord. 1998;51(3):215–235.
   PubMed Web of Science ®Google Scholar
• Newhouse PA, Krishnan KRR, Doraiswamy PM, et al. A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients. J Clin Psychiat. 2000;61(8):559–568.
   PubMedGoogle Scholar
• Mendlowicz MV, Stein MB. Quality of life in individuals with anxiety disorders. A J Psychiat. 2000;157(5):669–682.
   Web of Science ®Google Scholar
• Curtiss J, Klemanski DH. Taxonicity and network structure of generalized anxiety disorder and major depressive disorder: an admixture analysis and complex network analysis. J Affect Disord. 2016;199:99–105.
   PubMed Web of Science ®Google Scholar
• Curtiss J, Klemanski DH. Identifying individuals with generalised anxiety disorder: a receiver operator characteristic analysis of theoretically relevant measures. Behav Change. 2015;32(04):255–272.
   Web of Science ®Google Scholar
• Hofmann SG, Mundy EA, Curtiss J. Neuroenhancement of exposure therapy in anxiety disorders. AIMS Neurosc. 2014;2(3):123–138.
   Google Scholar
• Hofmann SG, Meuret AE, Smits JA, et al. Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiat. 2006;63(3):298–304.
   PubMed Web of Science ®Google Scholar
• Hofmann SG, Wu JQ, Boettcher H. D-Cycloserine as an augmentation strategy for cognitive behavioral therapy of anxiety disorders. Biol Mood Anxiety Disord. 2013;3(11):1–10.
   PubMedGoogle Scholar
• Guastella AJ, Richardson R, Lovibond PF, et al. A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. Biol Psychiat. 2008;63(6):544–549.
   PubMed Web of Science ®Google Scholar
• Smits JA, Rosenfield D, Otto MW, et al. D-Cycloserine enhancement of fear extinction is specific to successful exposure sessions: evidence from the treatment of height phobia. Biol Psychiat. 2013;73(11):1054–1058.
   PubMed Web of Science ®Google Scholar